Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 20/20 | 0.78 |
| ▸ | ATR | Q13535 | 3/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | MTOR | P42345 | 11/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18632019 | 0.87 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18631949 | 0.86 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL29565807 | 0.86 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL20839523 | 0.85 | ATM (0.77) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18631935 | 0.85 | ATM (0.97) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL25989795 | 0.83 | ATM (0.80) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18631986 | 0.81 | ATM (0.79) | ATMATRKCNH2MTORPIK3CA | |
| Azd-1390 SCHEMBL29565675 | 0.81 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| Azd-1390 SCHEMBL18631972 | 0.81 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL19584960 | 0.80 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856255-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-01-02 | — | — | US | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 10/4885KCNH2 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.